Severe side effects in patients with B-cell chronic lymphocytic leukemia (CLL) and lymphocytosis treated with the monoclonal anti-CD20 antibody rituximab.

被引：0
|
作者：
Winkler, U [1 ]
Jensen, M [1 ]
Manzke, O [1 ]
Tesch, H [1 ]
Bohlen, H [1 ]
Diehl, V [1 ]
Engert, A [1 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, Cologne, Germany
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4228
引用
收藏
页码：285B / 285B
页数：1
相关论文
共 50 条
  • [21] Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies
    Caitlin M. McNulty
    Emasenyie A. Isikwei
    Pragya Shrestha
    Melissa R. Snyder
    Brian F. Kabat
    Kari G. Rabe
    Susan L. Slager
    Sameer A. Parikh
    Avni Y. Joshi
    Journal of Hematopathology, 2020, 13 : 221 - 229
  • [22] Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies
    McNulty, Caitlin M.
    Isikwei, Emasenyie A.
    Shrestha, Pragya
    Snyder, Melissa R.
    Kabat, Brian F.
    Rabe, Kari G.
    Slager, Susan L.
    Parikh, Sameer A.
    Joshi, Avni Y.
    JOURNAL OF HEMATOPATHOLOGY, 2020, 13 (04) : 221 - 229
  • [23] Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Previously Untreated Chronic Lymphocytic Leukemia
    Shah, Arpita
    ANNALS OF PHARMACOTHERAPY, 2014, 48 (10) : 1356 - 1361
  • [24] Genetic and clinical relation between monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)
    Kern, W.
    Haferlach, C.
    Dicker, F.
    Schnittger, S.
    Haferlach, T.
    ONKOLOGIE, 2010, 33 : 20 - 21
  • [25] Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia
    Nightingale, Ginah
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (10) : 1248 - 1255
  • [26] Citrobacter koseri Cellulitis During Anti-CD20 Monoclonal Antibody (Ofatumumab) Treatment for B-cell Chronic Lymphocytic Leukaemia
    Kluger, Nicolas
    Cartron, Guillaume
    Bessis, Didier
    Guillot, Bernard
    Girard, Celine
    ACTA DERMATO-VENEREOLOGICA, 2010, 90 (01) : 99 - 100
  • [27] Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
    Zelenetz, Andrew David
    Mato, Anthony R.
    Robak, Tadeusz
    Jones, Jeffrey Alan
    Pagel, John M.
    Barrientos, Jacqueline Claudia
    Brown, Jennifer R.
    Montillo, Marco
    Kipps, Thomas J.
    Dubowy, Ronald
    Xing, Guan
    Li, Julia
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Anti-cd20 monoclonal antibody treatment (rituximab) in acute lymphoblastic leukemia
    Jándula, BM
    Nomdedeu, J
    Marín, P
    Muñoz, L
    Vivancos, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S92 - S92
  • [29] CD49D EXPRESSION IS ASSOCIATED WITH DEVELOPMENT OF LYMPHADENOPATHY IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Strati, P.
    Chaffee, K.
    Achenbach, S.
    Slager, S.
    Call, T.
    Kay, N.
    Ding, W.
    Parikh, S.
    Jelinek, D.
    Hanson, C.
    Shanafelt, T.
    HAEMATOLOGICA, 2016, 101 : 435 - 436
  • [30] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
    Witzens, M
    Gemmel, C
    Moos, M
    Goldschmidt, H
    Ho, AD
    BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
12345